Wenxin Zheng, M.D., Tenured Professor of Pathology, Obstetrics and Gynecology, American board certified pathologist, graduated from Shanghai Medical College Fudan University and trained at Columbia University, Cornell University, and Brown University Medical Centers in anatomic pathology and gynecologic pathology, Selected by US News and World Report in 2013 as one of America's top pathologists, Dr. Zheng is an internationally recognized gynecologic pathologist with outstanding expertise in every aspect of gynecologic pathology.  Dr. Zheng’s main research contributions include endometrial serous carcinogenesis and precancerous lesion endometrial glandular dysplasia, cell origin of low-grade ovarian serous carcinoma, hormonal etiology of ovarian epithelial cancers, and tubal contribution of ovarian endometriosis and its associated ovarian cancers.  In addition to these, Dr. Zheng has created a novel approach called "One Stop Cervical Care (OSCC)" to diagnose and treat cervical precancers. 


Medical School
Shanghai Medical College of Fudan University (1982)
Hospital of Obstetrics and Gynecology (1983), Obstetrics & Gynecology
Hospital of Obstetrics and Gynecology (1986), Obstetrics & Gynecology
Columbia University Medical Center (1989), Molecular Reproduction
Cornell New York Presbyterian Hospital (1995), Pathology
Brown University Woman & Infant Hospital (1996), Gynecologic Pathology

Research Interest

  • Biomarkers to aid the diagnosis of gynecologic cancers
  • Cervical cancer: suitable model of cervical cancer screening, effective intervention, and prevention in developing countries.
  • Endometrial serous carcinoma: carcinogenesis, early detection and prevention
  • Ovarian cancer early detection and prevention
  • Tubal origin of ovarian endometriosis and its related cancer development
  • Tubal secretory cell biology


Featured Publications LegendFeatured Publications

Tubal origin of ovarian endometriosis.
Yuan Z, Wang L, Wang Y, Zhang T, Li L, Cragun JM, Chambers SK, Kong B, Zheng W Mod. Pathol. 2014 Aug 27 8 1154-62
IMP3 signatures of fallopian tube: a risk for pelvic serous cancers.
Wang Y, Wang Y, Li D, Li L, Zhang W, Yao G, Jiang Z, Zheng W J Hematol Oncol 2014 Jul 7 1 49
Secretory cell expansion with aging: risk for pelvic serous carcinogenesis.
Li J, Ning Y, Abushahin N, Yuan Z, Wang Y, Wang Y, Yuan B, Cragun JM, Chambers SK, Hatch K, Kong B, Zheng W Gynecol. Oncol. 2013 Dec 131 3 555-60
Tubal origin of ovarian low-grade serous carcinoma.
Chen C, Li J, Yao G, Chambers SK, Zheng W Am J Clin Exp Obstet Gynecol 2013 Dec 1 1 13-36
Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium.
Wang Y, Wang Y, Li J, Cragun J, Hatch K, Chambers SK, Zheng W J Hematol Oncol 2013 Mar 6 1 22
Detection of PAX8 and p53 is beneficial in recognizing metastatic carcinomas in pelvic washings, especially in cases with suspicious cytology.
Xiang L, Zheng W, Kong B Gynecol. Oncol. 2012 Dec 127 3 595-600
Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach.
Fadare O, Zheng W Am J Cancer Res 2012 2 3 335-9
Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.
Zheng W, Fadare O Int J Clin Exp Pathol 2012 5 3 182-6
Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis.
Li J, Fadare O, Xiang L, Kong B, Zheng W J Hematol Oncol 2012 5 8
Tubal origin of 'ovarian' low-grade serous carcinoma.
Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, Kong B, Zheng W Mod. Pathol. 2011 Nov 24 11 1488-99


Featured Books Legend Featured Books